Dr. Sanacora is the George and Ester Gross Professor of Psychiatry, Director of the Yale Depression Research Program, and Co-Director of Yale’s Interventional Psychiatry Program. Dr. Sanacora’s work employs both preclinical and clinical research methodologies in attempts to expand our understanding of the underlying pathophysiology of neuropsychiatric disorders and mechanisms of effective treatment actions, with the goal of ultimately developing novel diagnostic and treatment approaches. He has served as PI on numerous NIH, foundation, and industry sponsored studies ranging from rodent models of pathogenesis, through mechanistic neuroimaging studies introducing novel methods to assess brain metabolism, to large multi-center phase III clinical trials. His personal experience over the arc of this journey has provided him with unique perspectives on the challenges that impede the successful application of neuroscience advances to neuropsychiatric clinical practice and led him to foster a diverse interdisciplinary collaborative team approach to translational neuroscience. In recognition of these efforts he recently received the 2022 Association for Clinical and Translational Sciences award for Team Science in addition to previous awards including the Anna-Monkia Stiftung international award for investigation of the biological substrate and functional disturbances of depression, the Joel Elkes Research Award for Outstanding contributions to Psychopharmacology from the American College of Neuro-Psychopharmacology.

Policy on Faculty and Sponsor Disclosure

It is the policy of the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) to identify, mitigate and disclose all relevant financial relationships with ineligible companies* held by the speakers/presenters, authors, committee members, planners, and other persons who may influence content of this accredited continuing education (CE). In addition, speakers/presenters and authors must disclose any planned discussion of unlabeled/unapproved uses of drugs or devices during their presentation(s). For this accredited continuing education activity all relevant financial relationships have been mitigated and detailed disclosures are listed below.

*Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by, or on, patients. The ACCME does not consider providers of clinical services directly to patients to be ineligible companies.